Expressing concerns about generic competition, a House committee asked Allergan (AGN) to provide a slew of documents about its controversial deal to sell patents on a best-selling drug to a Native American tribe.
In a letter sent on Tuesday to Allergan chief executive officer Brent Saunders, the Committee on Oversight and Government Reform wants the drug maker to cough up agreements, contracts, and analysis pertaining to the sale. An Allergan spokesman wrote us that the company intends to comply with the request.
About the Author Reprints
